https://images.mktw.net/im-88097946
Published:
Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to about $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, the company said on Tuesday.
Verve’s stock
VERV soared 76% in premarket trading on Tuesday. If the gains hold through the trading session, they’ll eclipse the previous record one-day gain of 28% for the company’s stock on Oct. 31, 2023, according to FactSet data.
